Back to Journals » Clinical Interventions in Aging » Volume 8

A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly

Authors Gras-Miralles B, Cremonini F

Received 24 October 2012

Accepted for publication 17 December 2012

Published 15 February 2013 Volume 2013:8 Pages 191—200

DOI https://doi.org/10.2147/CIA.S30729

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Beatriz Gras-Miralles,1 Filippo Cremonini1,2

1Gastroenterology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 2Southern Nevada VA Healthcare System, Las Vegas, NV, USA

Abstract: Chronic constipation is a common disorder in the general population, with higher prevalence in the elderly, and is associated with worse quality of life and with greater health care utilization. Lubiprostone is an intestinal type-2 chloride channel activator that increases intestinal fluid secretion, small intestinal transit, and stool passage. Lubiprostone is currently approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation and of irritable bowel syndrome with predominant constipation. This review outlines current approaches and limitations in the treatment of chronic constipation in the elderly and discusses the results, limitations, and applicability of randomized, controlled trials of lubiprostone that have been conducted in the general and elderly population, with additional focus on the use of lubiprostone in constipation in Parkinson's disease and in opioid-induced constipation, two clinical entities that can be comorbid in elderly patients.
Keywords: irritable bowel syndrome, Parkinson's disease, opioid-induced constipation, chronic constipation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]